Table 3 Prioritised research projects for 2018, 2019 and 2020
From: International severe asthma registry (ISAR): protocol for a global registry
Project | Investigator |
|---|---|
2018 | |
Biologics in severe asthma: utilisation patterns, causes for discontinuation and switching and adverse outcomes | Professor Andrew Menzies-Gow (UK) |
Hidden severe asthma patients in primary care vs. ISAR | Professor David Price (Singapore) |
Relationship between socioeconomic status and asthma outcomes | Professor Liam Heaney (UK) |
The impact of exacerbation burden on lung function trajectory in a broad asthma population and severe asthma population | Professor Liam Heaney (UK) |
Biomarker Relatability in the International Severe Asthma Registry (BRISAR) | Dr. Eve Denton and Dr. Mark Hew (Australia) |
Identification of predictors (i.e. biomarkers) of response to biologics | Dr. Eve Denton and Dr. Mark Hew (Australia) |
Hidden chronic asthma within the COPD/ACO population | Professor Chin Kook Rhee (South Korea) |
Age of onset of asthma in severe asthma patients | Dr. Enrico Heffler (Italy) |
2019 | |
Describe the OCS landscape: annual consumption, prevalence, outcomes and side effects of long-term OCS users | |
Criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma | |
2020 | |
What is the impact of co-morbidity in severe asthma? | |
Define responders and non-responders to biologics and describe their characteristics overall and per biologic | |
Describe the clinical outcome before and after biologic treatment by biologic class, by individual biologic, and by subgroups of baseline characteristics | |